Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer

• Alessandro Passardi ,

  * E-mail: alessandro.passardi@irst.emr.it

  Affiliation Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  ⨯
• Emanuela Scarpi,

  Affiliation Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola, Italy

  ⨯
• Stefano Tamberi,

  Affiliation Oncology Unit, Degli Infermi Hospital, Faenza, Italy

  ⨯
• Luigi Cavanna,

  Affiliation Medical Oncology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy

  ⨯
• Davide Tassinari,

  Affiliation Department of Oncology, Per gli Infermi Hospital, Rimini, Italy

  ⨯
• Annalisa Fontana,

  Affiliation Oncology Unit, University Hospital Modena, Modena, Italy

  ⨯
• Sara Pini,

  Affiliation Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  ⨯
• Ilaria Bernardini,

  Affiliation Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy

  ⨯
• Caterina Accettura,

  Affiliation Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy

  ⨯
• Paola Ulivi,

  Affiliation Biosciences Laboratory, IRST IRCCS, Meldola, Italy

  ⨯
• Giovanni Luca Frassineti,

  Affiliation Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  ⨯
• Dino Amadori

  Affiliation Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  ⨯